A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

Summary

This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.

Timeline

Start

2024-06-18

Primary completion

2024-10-10

Completion

2024-12-06

Outcome

Met primary endpoint

release “The study met its primary objectives: TE-8214 demonstrated good safety, tolerability, and pharmacological activity” immunwork.com ↗

Drugs

Indications